Citadel Advisors
SOPH icon

Citadel Advisors’s SOPHiA GENETICS SOPH Stock Holding History

Citadel Advisors’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$145K Buy
+29,200
New +$142K ﹤0.01% 11717
2025
Q2 		– Sell
-500
Closed -$1.66K – 14896
2025
Q1 		$1.66K Sell
500
-500
-50% -$1.76K ﹤0.01% 14115
2024
Q4 		$3.12K Sell
1,000
-4,900
-83% -$16.7K ﹤0.01% 14024
2024
Q3 		$21.4K Buy
+5,900
New +$24K ﹤0.01% 12726
2024
Q1 		– Sell
-100
Closed -$471 – 15381
2023
Q4 		$471 Hold
100
– – ﹤0.01% 14024
2023
Q3 		$255 Hold
100
– – ﹤0.01% 14109
2023
Q2 		$448 Buy
+100
New +$452 ﹤0.01% 14118

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $369M AUM 45.79% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Citadel Advisors's SOPH Position: Q4 2025 in Review

Citadel Advisors sold out of SOPHiA GENETICS (SOPH) in Q4 2025, closing a stake of 12,320 shares — an estimated $58.6K sold.

Citadel Advisors first reported a position in SOPH in Q4 2021 and held it in 12 quarters. The position peaked at $334K in Q1 2023. 42 funds tracked by Wall St. Rank hold SOPH as of Q4 2025.

  • Citadel Advisors reported no remaining SOPHiA GENETICS position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,320 SOPHiA GENETICS shares in Q4 2025, an estimated $58.6K.
  • Citadel Advisors first reported a position in SOPHiA GENETICS in Q4 2021 and held it in 12 quarters.
  • Citadel Advisors's SOPHiA GENETICS position peaked at $334K in Q1 2023.
  • 42 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.